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tolerance if the benefits are changed. However, DCE seems to be more sensitive 
for a change in benefits and risks while the MAR estimates obtained through 
BWS have considerably lower uncertainty than DCE.  
 
PMS50  
RAPID IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH 
CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, 
INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL 
SPONDYLOARTHRITIS: 24-WEEK RESULTS OF A PHASE 3 DOUBLE BLIND 
RANDOMIZED PLACEBO-CONTROLLED STUDY  
Sieper J1, Kivitz A2, van Tubergen A3, Deodhar A4, Coteur G5, Woltering F6, Landewé R7 
1Univ Hospital Charité, Berlin, Germany, 2Altoona Center for Clinical Research, Duncansville, PA, 
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OBJECTIVES: RAPID-axSpA (NCT01087762) investigated the impact of 
certolizumab pegol (CZP) on patient reported outcomes (PRO) in axial 
spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-
radiographic axSpA (nr-axSpA, axSpA with no definitive sacroiliitis on X-ray). 
METHODS: The ongoing 158-week (Wk) RAPID-axSpA trial was double blind and 
placebo-controlled to Wk24. Recruited patients had adult-onset active axSpA, 
including AS and nr-axSpA. Patients were randomized 1:1:1 to placebo, or 400mg 
CZP at Wk0, two and four followed by either 200mg CZP every two weeks (Q2W) 
or 400mg CZP every four weeks (Q4W). PRO endpoints included, physical 
function (BASFI), total spinal pain, daily pain diary to Wk4, fatigue (from 
BASDAI), Ankylosing Spondylitis Quality of Life (AsQoL), Sleep Problems Index II 
domain of the MOS Sleep scale, and SF-36. Change from baseline in PRO was 
analyzed in full analysis set with LOCF imputation. RESULTS: A total of 325 
patients were randomized. Baseline characteristics were similar between groups. 
Compared to placebo, improvements at Wk24 in CZP 200mg Q2W and 400mg 
Q4W treated groups were observed in pain (-1.3 vs. -3.3 and -3.2), fatigue (-0.9 vs. 
-2.6 and -2.8), BASFI (-0.5 vs. -2.4 and -2.2) and AsQoL (-1.7 vs. -5.1 and -5.1). 
Improvements were seen from Wk1, and in spinal pain from day 2. CZP-treated 
patients also had greater improvements in sleep, and SF-36 components and 
domains. More CZP patients reached population norms for SF-36. CZP impact on 
pain, fatigue and AsQoL in AS and nr-axSpA patients was similar. Relative to 
placebo, CZP-treated nr-axSpA patients demonstrated greater improvements in 
BASFI and sleep compared to AS, and were more likely to reach population 
norms for SF-36. CONCLUSIONS: Both dosing regimens of CZP rapidly improved 
all PRO including pain, fatigue, physical function and QoL of axSpA, in both AS 
and nr-axSpA patients.  
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EFFECT OF CERTOLIZUMAB PEGOL ON THE MULTIPLE FACETS OF PSORIATIC 
ARTHRITIS AS REPORTED BY PATIENTS: 24-WEEK PATIENT REPORTED 
OUTCOME RESULTS OF A PHASE 3 DOUBLE BLIND RANDOMIZED PLACEBO-
CONTROLLED STUDY  
Gladman D1, Fleischmann R2, Coteur G3, Woltering F4, Mease P5 
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OBJECTIVES: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient reported outcomes (PRO) in psoriatic arthritis (PsA), as 
investigated in RAPID-PsA (NCT01087788). METHODS: The ongoing 158 week 
(Wk) RAPID-PsA trial is double blind and placebo-controlled to Wk24. Recruited 
patients had active PsA and had failed ≥1 DMARD. Patients could have received 1 
previous anti-TNF. Patients were randomized 1:1:1 to placebo, or 400mg CZP  
at Wk 0, 2 and 4 (loading dose) followed by either 200mg CZP every 2 weeks 
(Q2W) or 400mg CZP every 4 weeks (Q4W). PRO measures evaluated: fatigue 
assessment scale (FAS), patient assessment of pain (VAS), health assessment 
questionnaire-disability index (HAQ-DI), SF-36, PsAQoL, and the Dermatology 
Life Quality Index (DLQI). Change from baseline for PRO was analyzed for  
the randomized population, with LOCF imputation. RESULTS: A total of 409 
patients were randomized. 20% of patients had received a prior anti-TNF. 
Baseline demographics were similar between groups. From baseline to Wk24, 
differences in pain (-11.2 vs. -28.6 and -28.4), fatigue (-0.6 vs. -2.2 and -1.9), HAQ-
DI (-0.19 vs. -0.54 and -0.46), SF-36 physical component summary (2.14 vs. 8.43 
and 7.58) and mental component summary (0.73 vs 5.49 and 3.49), PsAQoL (-1.27 
vs. -4.43 and -3.30), and DLQI (-1.4 vs. -6.3 and -5.2) were observed in placebo vs. 
CZP 200mg Q2W and 400mg Q4W arms (p<0.001). Differences were observed 
from Wk1 and were irrespective of prior anti-TNF exposure. More patients on 
CZP reached SF-36 general population norms than placebo patients. 
CONCLUSIONS: CZP effectively improved multiple PROs in PsA patients across 
many disease facets. The benefits of CZP treatment on physical and emotional 
components of HRQoL were seen across generic, PsA-specific and dermatology-
specific measures. These benefits were seen in patients regardless of prior anti-
TNF exposure.  
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THE IMPORTANCE OF MANAGING ARTHRITIS IN PATIENTS WITH BOTH 
MODERATE-TO-SEVERE PSORIASIS AND PSORIATIC ARTHRITIS  
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OBJECTIVES: To determine the impact of improvements in skin and 
musculoskeletal components on quality of life (QoL), we studied patients with 
both moderate-to-severe psoriasis and psoriatic arthritis (PsA) treated with 
etanercept (ETN). METHODS: Ad hoc analyses were performed on pooled data 
from the PRESTA trial in which patients were randomized to ETN 50 mg once 
weekly (QW) for 12 weeks or ETN 50 mg twice weekly for 12 weeks, followed by 
ETN 50 mg QW for 12 weeks. Dermatologists evaluated skin disease using the 
Psoriasis Activity and Severity Index (PASI) endpoints PASI50 (50% improvement) 
and PASI75 (75% improvement). Rheumatologists evaluated arthritis using the 
American College of Rheumatology (ACR) endpoints of ACR20 and ACR50 (≥20% 
and ≥50% improvement in ACR core criteria, respectively). To measure QoL, 
patients completed the EuroQoL-5 Dimension (EQ-5D) utility (scale 0–1, higher 
scores=better QoL, minimal important difference [MID]=0.05) and Visual Analog 
Scale (VAS; scale 0–100, higher scores=better health state, MID=5) questionnaire. 
RESULTS: Improvements from baseline at week 24 in EQ-5D utility and VAS 
scores for patients achieving ACR50 but not PASI75 (n=89) were significantly and 
clinically meaningfully greater than patients achieving PASI75 but not ACR50 
(n=193; EQ-5D utility Δ=0.327 vs. 0.199, P<0.001; EQ-5D VAS Δ=23.7 vs. 15.1, 
P=0.002). Similarly, improvements for patients achieving ACR20 but not PASI50 
(n=55) were significantly greater than those achieving PASI50 but not ACR20 
(n=163; EQ-5D utility Δ=0.385 vs. 0.134, P<0.001; EQ-5D VAS Δ=19.3 vs. 10.4, 
P=0.005). CONCLUSIONS: Patients with both moderate-to-severe psoriasis and 
PsA showing greater improvements in arthritis than psoriasis reported more QoL 
gains compared with those with greater improvements in psoriasis than 
arthritis. Although the ACR response and PASI measures are formed of different 
components, the magnitude of the QoL gain with improvement in arthritis 
shows that the arthritis component of psoriatic disease contributes significantly 
to reduced QoL.  
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OBJECTIVES: To assess the physical component score (PCS), mental component 
score (MCS), and EuroQol (EQ5D) score of RA and non-RA patients. METHODS: 
Retrospective analysis of civilian non-institutionalized Medical Expenditures 
Panel Survey (MEPS) data for the year 2006. 20,434 respondents had positive 
weight, had complete information, and who were atleast 18 years were included 
in the analysis. Clinical Classification Code 202 identified RA respondents. RA 
and Non-RA respondents were matched on age, gender, race, education, marital 
status, income, region, insurance, and comorbidity index score. Since the MEPS 
2006 consists of only PCS and MCS, a mapping algorithm was used to derive EQ-
5D score. Proc surveyfreq, and proc surveymeans to describe the demographic 
characteristics. T-tests were used to measure statistical differences in QOL 
scores between the 2 groups. RESULTS: Among adults with RA, 86.75% were 
whites with mean (SE) age of 59.83 (1.18) years and 80% were females. The mean 
(SE) PCS scores for the RA and Non-RA group was 34.25 (1.35) and 45.46 (1.30). 
The mean (SE) MCS scores for the RA and Non-RA group was 47.49 (1.09) and 
51.14 (0.86). The mean (SE) EQ-5D index score for the RA and Non-RA groups was 
0.74 (0.02) and 0.86 (0.01). The results were significant at an apriori alpha value of 
0.05. CONCLUSIONS: Since the disease conditions were self-reported and 
institutionalized persons were not included, the true prevalence of RA may be 
underestimated. All QOL scores for RA patients were lower in the 2006 MEPS data 
indicating that respondents with RA have reduced QOL. RA significantly impairs 
QOL in the U.S. population. The study trengthens the importance of treating RA. 
This study did not differentiate QOL by severity of RA. RA-specific QOL measures 
were unavailable in MEPS.  
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OBJECTIVES: Examine impact of ustekinumab treatment on general &disease-
specific patient reported outcomes (PROs) of patients with active PsA using 
PSUMMIT1 data. METHODS: Adult PsA patients (n=615) with active disease 
despite DMARD&/or NSAID therapy were randomized to ustekinumab 45mg, 
90mg, or PBO at wks0, 4, &q12wks, thereafter. Patients treated with prior anti-
TNF agents were excluded. At wk16, patients with <5% improvement in SJC/TJC 
entered blinded EE (PBO→ustekinumab 45mg; ustekinumab 45mg→90mg; 
90mg→90mg). PROs were measured with HAQ, DLQI, SF-36, &VAS for impact of 
PsA on work productivity (0-10), patient assessment of pain (0-10)& disease 
activity (0-10). ANOVA on van der Waerden normal scores was used for 
continuous variables & chi-square or the Cochran-Mantel-Haenszel (CMH) test 
for binary variables between groups. RESULTS: Baseline PRO measures indicated 
the study population had severe physical disability& impaired HRQoL, with 
mean HAQ score of 1.25 &mean DLQI score of ≥10. At wk24, greater 
improvements in: HAQ (0.31&0.4 vs. 0.1, P<0.001), DLQI (6.6&7.5 vs. 1.4, P<0.001), 
SF-36 PCS (4.9 &6.2 vs. 1.4, P<0.001)& MCS (3.4&4.8 vs. 1.5, p<0.01 90 mg only) 
were observed in ustekinumab 45mg &90mg groups vs PBO, respectively. 
Proportions of patients who achieved clinical meaningful improvements in HAQ 
≥0.3 (47.8% &47.5% vs. 28.2%, P<0.001), DLQI ≥5 (58.6% &63.1% vs. 32.9%, P<0.001), 
&SF-36 PCS ≥5(46.5% &53.3% vs. 26.0%, P<0.001) &MCS ≥5(37.0% &47.7% vs. 33.7%, 
p<0.01 90mg only) were greater in ustekinumab 45mg &90mg group vs PBO, 
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respectively. Ustekinumab 45mg&90mg -treated patients achieved greater 
improvements in patient assessment of pain (25.9% &29.6% vs. 4.5%, P<0.001), 
patient assessment of disease activity (25.4% &27.6% vs. 7.6%, P<0.001)& greater 
reduction in impact of disease on work productivity (1.82& 2.64 vs. 0.78, P<0.001) 
versus PBO-treated patients, respectively. CONCLUSIONS: Ustekinumab 
improves general as well as arthritis &skin-related QoL, &reduces the impact of 
disease on work productivity in patients with active PsA.  
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A EUROPEAN ASSESSMENT OF THE IMPACT OF INADEQUATE PAIN RELIEF (IPR) 
ON HEALTH-RELATED QUALITY OF LIFE (QOL) IN PATIENTS WITH KNEE 
OSTEOARTHRITIS (OA) IN THE SURVEY OF REAL WORLD THERAPIES (SORT)  
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OBJECTIVES: To describe inadequate pain relief (IPR) and evaluate its impact on 
QOL in patients with knee osteoarthritis. METHODS: SORT, a 12-month 
prospective study across 6 EU countries (N=1,260), enrolled participants >50 years 
old with knee OA who were prescribed pain medications. Clinical history and 
QOL (generic and disease-specific) were collected at baseline and months 1, 3, 6, 
9 and 12. Inadequate Pain Relief (IPR) was defined as a Brief Pain Inventory (BPI) 
pain score of "moderate or greater pain" (score >4). Statistical analyses of 
baseline data were conducted. RESULTS: Evaluable baseline data are presented 
for 1217 participants: 67.6% women; mean age 68 (SD=9.4) years; mean duration 
of OA 5.9 years (SD=6.2) and 83.4% reported taking oral pain medications. IPR 
comprised 54% of the cohort (656 of 1217). IPR participants reported more 
disability (14.3% vs. 9.3%, p=0.013), greater number of co-morbidities (p<0.0001) 
and were taking more opioid-containing medications (27.1% vs. 16.3%, p<0.001) 
than those with pain relief. IPR participants had worse WOMAC scores: stiffness 
(56.9 vs. 33.6, p<0.001), pain (53.2 vs. 28.4, p<0.001) and physical function (54.9 vs. 
29.9, p<0.001). IPR participants reported significant worse scores for pain severity 
(5.8 vs. 2.7, p<0.001) and pain interference (5.3 vs. 2.4, p<0.001) as measured by 
BPI. General health status was lower for IPR participants with 51.2% vs. 29.0% 
(p<0.001) reporting fair/poor health. IPR participants scored worse on all SF-12 
domains with differences for the physical component summary (PCS) (35.1 vs. 
41.4, p<0.001) and mental component summary (MCS) (45.7 vs. 52.0, p<0.001). 
CONCLUSIONS: SORT found over half of participants reported inadequate pain 
relief (i.e., moderate to severe pain). IPR participants experienced more co-
morbidities and significant QOL impairments as demonstrated by poorer health 
status, greater pain, physical limitations and stiffness than participants with 
pain relief. The presented SORT baseline data support the relationship between 
IPR and reduced QOL.  
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OBJECTIVES: International Osteoporosis Foundation Quality of Life questionnaire 
(QUALEFFO-41) is the specific questionnaire for the postmenopausal women 
with osteoporosis and vertebral fractures. Reliability of the questionnaire could 
be confirmed by sensitivity and specificity. The objective of this stidy is to test 
the sensitivity and specificity of the QUALEFFO-41 questionnaire. METHODS: A 
case-control study was conducted during the period of June 2010 - October 2011 
to test the main characteristics of the questionnaire. The study included 100 
patients with osteoporosis (50 cases with vertebral fractures and 50 controls 
without fractures). The questionnaire EQ-5D (with direct-scoring) was used for 
comparison of the results with the QUALEFFO-41 (with reverse-scoring). The 
study was performed in two medical centers in Serbia. RESULTS: The results of 
the ROC curve analysis (between the case and control group of patients) 
indicated that the AUC ranges for all five dimensions of the QUALEFFO-41 
questionnaire and the total score were 0.62–0.69. The QUALEFFO-41 had a better 
prediction of the value of HRQOL of cases compared to the generic questionnaire 
EQ-5D (the AUC difference of the total scores was 0.099, p=0.013). Correlations 
between the total scores of the QUALEFFO-41 and the EQ-5D health state value, 
for both groups, were negative and statistically significant (r=-0.78, p<0.001 and r 
= -0.73, p<0.001, respectively). CONCLUSIONS: The QUALEFFO-41 has the ability 
to detect the patients with osteoporosis and vertebral fractures among the 
osteoporosis patients. This questionnaire is more specific for the osteoporosis 
patients with fractures in relation to the EQ-5D questionnaire.  
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THE PERSONAL DISEASE AND TREATMENT BURDENS OF KOREAN ELDERLY 
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OBJECTIVES: To explore the personal experiences of Korean elderly women who 
have sustained osteoporotic fragility fractures regarding their disease and 
treatment burdens. METHODS: The research design was a qualitative descriptive 
study. Open-ended questions were asked of twelve Korean elderly women who 
experienced at least two osteoporotic fractures. They participated in an in-depth 
face-to-face interview. Data were analyzed using qualitative content analysis 
method, which is an inductive process following eight steps developed by Downe-
Wamboldt. RESULTS: Five themes were identified: 1) physically living with pain and 
disability following unexpected fractures; 2) financially facing a penniless old age 
and unaffordable treatment cost; 3) emotionally feeling the unbridgeable gap 
between desired life and the present; 4) cognitively having health illiteracy and 
medical ignorance; and 5) socially and spiritually copying with pain and trying to be 
free from their suffering lives. CONCLUSIONS: The interview participants described 
how they have suffered from chronic pains and a dysfunctional body after 
unexpected and recurrent fractures, which made their quality of life decrease. Since 
most women in this older generation have had low educational attainment and 
minimal financial preparations for their retirement years, they perceive the medical 
treatment cost of osteoporosis and their dependency on their own adult children as 
burdens. Therefore, Korean health care policy stakeholders and professionals need 
to develop medical assurance and osteoporotic fracture disease specific guidelines 
that are tailored to this generation.  
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IMPROVEMENTS IN PRODUCTIVITY AT PAID WORK AND WITHIN HOUSEHOLD, 
AND INCREASED PARTICIPATION IN DAILY ACTIVITIES AFTER 24 WEEKS OF 
CERTOLIZUMAB PEGOL TREATMENT OF PATIENTS WITH PSORIATIC 
ARTHRITIS: RESULTS OF A PHASE 3 DOUBLE BLIND RANDOMIZED  
PLACEBO-CONTROLLED STUDY  
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OBJECTIVES: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on productivity of paid and household work, and daily activities, in 
psoriatic arthritis (PsA). METHODS: Patients had active PsA and had failed ≥1 
DMARD. Patients were randomized 1:1:1 to placebo, or CZP 400mg at Week (Wk) 
0, 2 and 4 followed by either 200mg CZP every 2 weeks (Q2W) or 400mg CZP every 
4 weeks (Q4W). The arthritis-specific Work Productivity Survey (WPS, 
administered Q4W) was used to assess the impact of PsA on productivity at 
work, at home and daily activities. WPS responses (LOCF imputation) were 
compared between treatment arms using a non-parametric bootstrap-t method. 
RESULTS: A total of 409 patients were randomized. 56.6%, 60.1%, and 61.5% of 
patients in the placebo, CZP 200mg Q2W, and CZP 400mg Q4W groups were 
employed outside home at study baseline. Baseline workplace and household 
productivity was comparable between treatment arms. At baseline, PsA 
impacted workplace absenteeism, and presenteeism; however, PsA burden on 
household productivity and participation in social activities was greater. 
Compared to placebo, employed patients in both CZP groups reported a greater 
decrease in absenteeism (mean 1.6 vs. 0.2 and 0.6 days per month) and 
presenteeism (mean 3.5 vs. 1.3 and 2.1 days per month) at Wk24. Improvements 
were observed as early as Wk4. CZP groups also reported larger improvements in 
household productivity as early as Wk4 and continued up to Wk24, compared to 
placebo. CONCLUSIONS: CZP improved workplace productivity in patients with 
PsA by reducing absenteeism and presenteeism. CPZ also improved household 
productivity and increased participation in social and daily activities.  
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OBJECTIVES: Investigate the effect of certolizumab pegol (CZP), a PEGylated Fc-
free anti-TNF, on paid and household work productivity, and daily activities, in 
patients with axial spondyloarthritis (axSpA), including patients with ankylosing 
spondylitis (AS) and non-radiographic axSpA (nr-axSpA, axSpA with no 
definitive sacroiliitis on X-ray). METHODS: Recruited patients had adult-onset 
active axSpA, including AS and nr-axSpA. Patients were randomized 1:1:1 to 
placebo, or CZP 400mg at Week (Wk) 0, 2 and 4 followed by either CZP 200mg 
every two weeks (Q2W) or CZP 400mg every four weeks (Q4W). The arthritis-
specific Work Productivity Survey (WPS, administered Q4W) assessed the impact 
of axSpA on workplace and household productivity. WPS responses (LOCF 
imputation) were compared between treatment arms using a non-parametric 
bootstrap-t method. RESULTS: A total of 325 patients were randomized. At 
baseline, 63.2%, 69.4%, and 74.8% of placebo, CZP 200mg Q2W, and CZP 400mg 
Q4W group patients were employed outside the home. Baseline workplace and 
household productivity was similar between groups. Baseline burden of axSpA 
on workplace and household productivity was high. Compared to placebo, 
employed patients in CZP 200mg Q2W and 400mg Q4W groups reported reduced 
absenteeism (mean 2.0 vs 1.1 and 0.6 days per month) and presenteeism (mean 
4.4 vs 2.4 and 2.7 days per month) at Wk24. Improvements were observed as 
early as Wk4. CZP groups reported greater reductions vs placebo in lost days of 
household work and of family/social/leisure activities per month, in days with 
reduced household productivity and in axSpA interference with household 
duties as early as Wk4 through to Wk24. Similar improvements were reported in 
both AS and nr-axSpA populations. CONCLUSIONS: CZP improved workplace 
productivity in patients with axSpA by reducing absenteeism and presenteeism. 
